| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Respiratory System | ||
PDUFA Date example | PDUFA | — | Subscribe to access the data. | Small Molecules | Respiratory System |
Recent Updates
Recently added Catalysts
Apnimed, Inc. Common Stock
$21.51
-0.61 (-2.71%)
Market Cap
895.48 M
EPS
-
P/E Ratio
-
Value Trade
9.83 M
1.99 %
Week
-22.71 %
1 Month
-13.96 %
3 Month
-13.96 %
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
681.99 K
52 Week Range
-
% held by Insiders
6.8 %
% held by Institutions
17.96 %
Enterprise Value
802.27 M
Total Shares
41.63 M
Short %
2.27 %
Float Shares
38.80 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Apnimed, Inc. Common Stock
32Total events
3Upcoming
7Tier-1 (high impact)
2025 – 2027Coverage
Upcoming catalysts 2
TBD
T1PDUFA Date
Subscribe to view catalyst details
TBD
T2Timing Guidance
Subscribe to view catalyst details
Event history 2
TBD
●Timing GuidancePresentation
Subscribe to view catalyst details
TBD
◆Oral PresentationAD109FiledPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
INSIDER TRANSACTIONSMonthly totals, since 2023
BuysSellsStock price
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in APMD
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
APMD Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-APMD
Oct 2, 2026▼ -2.7%today
Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Apnimed, Inc. announced the grant of stock options to 19 new non-executive employees under its 2026 Inducement Plan. Each option allows the purchase of shares at $22.54, vesting over four years. The company is focused on developing oral therapies for obstructive sleep apnea and is advancing its candidate AD109, which has completed two Phase 3 trials.
Read more →-APMD
Sep 8, 2026Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Apnimed, Inc. reported its second quarter 2026 financial results, highlighting the FDA's acceptance of its NDA for AD109, proposed as Oxnimbi, with a PDUFA date set for February 28, 2027. The company successfully completed an IPO, raising $220.8 million, and strengthened its leadership team. Oxnimbi aims to be the first oral treatment for obstructive sleep apnea, addressing a significant unmet need in the market.
Read more →-APMD
Aug 3, 2026Apnimed Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
Apnimed, Inc. has successfully closed its upsized initial public offering, raising $220.8 million through the sale of 13.8 million shares. The offering included the full exercise of underwriters' option to purchase additional shares. Apnimed's common stock began trading on the Nasdaq Global Select Market on July 31, 2026. The company is focused on developing novel therapies for sleep-related breathing diseases, particularly obstructive sleep apnea.
Read more →-APMD
Jul 31, 2026Apnimed Announces Pricing of Upsized Initial Public Offering
Apnimed, a late-stage clinical pharmaceutical company, has announced the pricing of its upsized initial public offering (IPO) of 12 million shares at $16.00 each. The IPO is expected to raise approximately $192 million, with shares set to begin trading on the Nasdaq Global Select Market on July 31, 2026. The offering includes a 30-day option for underwriters to purchase additional shares.
Read more →-APMD
Jul 14, 2026Apnimed Announces FDA Acceptance of New Drug Application for AD109, An Investigational Oral Pill to Treat Adults with Obstructive Sleep Apnea
Apnimed announced the FDA's acceptance of its New Drug Application for AD109, an investigational oral pill aimed at treating adults with obstructive sleep apnea (OSA). The FDA has set a target action date of February 28, 2027. If approved, AD109 could be the first oral pharmacologic therapy addressing the neuromuscular causes of OSA. The NDA is backed by positive results from Phase 3 clinical trials.
Read more →-APMD
Jul 1, 2026Apnimed Strengthens Leadership Team with Appointments of Industry Veterans Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs
Apnimed has appointed Michael Kelly as Chief Financial Officer and Steven Spector as Chief Legal Officer and Head of Corporate Affairs. This leadership transition follows the recent appointment of Kevin Lind as CEO and is part of a strategy to prepare the company for growth. Both Kelly and Spector bring significant experience in finance and legal compliance, respectively, as Apnimed advances towards the potential commercialization of its investigational drug AD109 for obstructive sleep apnea.
Read more →-APMD
Jun 10, 2026Apnimed Announces Upcoming Oral Presentation at SLEEP 2026 to Highlight Pooled Phase 3 Data for AD109 in Obstructive Sleep Apnea
Apnimed, Inc. announced that six abstracts, including an oral presentation, will be featured at SLEEP 2026, focusing on pooled Phase 3 data for AD109, its lead candidate for obstructive sleep apnea. The presentations underscore the urgent need for improved awareness and education regarding OSA, highlighting the challenges faced by patients in receiving timely treatment. AD109 aims to simplify intervention and improve patient outcomes in this chronic condition.
Read more →-APMD
Jun 8, 2026Apnimed Appoints Experienced Pharmaceutical Executive Kevin R. Lind as Chief Executive Officer to Implement Next Phase of Growth Strategy
Apnimed has appointed Kevin R. Lind as the new Chief Executive Officer, succeeding founder Lawrence G. Miller, MD, who will take on the role of Vice Chair of the Board. Mr. Lind brings extensive experience in the pharmaceutical industry, including leadership roles that have resulted in successful acquisitions. This leadership change is aimed at implementing the next phase of the company's growth strategy.
Read more →-APMD
May 18, 2026Apnimed Announces Publication of its Phase 3 SynAIRgy Trial of AD109 for Obstructive Sleep Apnea in the American Journal of Respiratory and Critical Care Medicine
Apnimed announced the publication of its Phase 3 SynAIRgy trial results for AD109, an investigational oral treatment for obstructive sleep apnea (OSA). The study demonstrated significant improvements in oxygenation and reductions in apnea-hypopnea index, supporting AD109's potential as a first-in-class therapy. A New Drug Application has been submitted to the FDA, with a target action date expected in early 2027.
Read more →-APMD
May 11, 2026Apnimed Announces Three Oral Presentations and a Late-breaking Poster at the American Thoracic Society (ATS) 2026 International Conference
Apnimed, Inc. announced multiple presentations at the ATS 2026 International Conference, including three oral presentations and a late-breaking poster. These will showcase findings from the Phase 3 trials of AD109, their lead product candidate for obstructive sleep apnea. The presentations aim to highlight the drug's efficacy in reducing snoring and cardiovascular risks associated with the condition.
Read more →Competitive Position
How APMD ranks across every disease it competes inCompetitive Position is a premium feature
See how APMD ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial